GEFITINIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H24ClFN4O3
Molecular Weight	446.902
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(OCCCN2CCOCC2)C=C3C(NC4=CC(Cl)=C(F)C=C4)=NC=NC3=C1

InChI

InChIKey=XGALLCVXEZPNRQ-UHFFFAOYSA-N

InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00317
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/gefitinib.html

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR tyrosine kinase in activating the Ras signal transduction cascade is inhibited; and malignant cells are inhibited. Gefitinib is the first selective inhibitor of the EGFR tyrosine kinase which is also referred to as Her1 or ErbB-1. EGFR is overexpressed in the cells of certain types of human carcinomas - for example in lung and breast cancers. Overexpression leads to inappropriate activation of the apoptotic Ras signal transduction cascade, eventually leading to uncontrolled cell proliferation. Gefitinib is used for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Epidermal growth factor receptor erbB1 58 Target ID: CHEMBL203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21334203	Antagonist 2778	1.0 nM [IC50]
BGC-823 2 Target ID: CHEMBL614526 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26703559	Inhibitor 8297	19.27 µM [IC50]
NCI-H1975 1 Target ID: CHEMBL614348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27118497	Inhibitor 8297	1.23 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Non-small cell lung cancer 206 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021399s008lbl.pdf	Primary		Approved 8429	Iressa Approved Use IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from IRESSA. Launch Date 2003

C_max

Value	Dose	Analyte	Population
57.45 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995orig1s000clinpharmr.pdf	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	GEFITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
724 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28579188	250 mg 1 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	GEFITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
57.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21487718	250 mg 1 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	GEFITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
579 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEFITINIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
178 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEFITINIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2160 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	700 mg 1 times / day multiple, oral dose: 700 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEFITINIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
213 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	GEFITINIB unknown	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2210 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995orig1s000clinpharmr.pdf	400 mg/m² 1 times / day multiple, oral dose: 400 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	GEFITINIB plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
1415 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995orig1s000clinpharmr.pdf	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	GEFITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
13103 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28579188	250 mg 1 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	GEFITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1415 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21487718	250 mg 1 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	GEFITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10026 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEFITINIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2985 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEFITINIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
42314 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	700 mg 1 times / day multiple, oral dose: 700 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEFITINIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
6181 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	GEFITINIB unknown	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
29.3 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995orig1s000clinpharmr.pdf	400 mg/m² 1 times / day multiple, oral dose: 400 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	GEFITINIB plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
23.83 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995orig1s000clinpharmr.pdf	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	GEFITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
25 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28579188	250 mg 1 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	GEFITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
21.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21487718	250 mg 1 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	GEFITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
38.1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEFITINIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
55.2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEFITINIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
72.9 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	700 mg 1 times / day multiple, oral dose: 700 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GEFITINIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
28.2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	GEFITINIB unknown	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
11.9 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995orig1s000clinpharmr.pdf	400 mg/m² 1 times / day multiple, oral dose: 400 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	GEFITINIB plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
9% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21487718	250 mg 1 times / day steady-state, oral dose: 250 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		GEFITINIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021399lbl.pdf			GEFITINIB plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1000 mg 1 times / day steady, oral Dose: 1000 mg, 1 times / day Route: oral Route: steady Dose: 1000 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25784657	unhealthy, 51 years (range: 46 – 72 years) n = 4 Health Status: unhealthy Condition: NSCLC Age Group: 51 years (range: 46 – 72 years) Sex: M+F Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/25784657	DLT: Toxic epidermal necrolysis... Dose limiting toxicities: Toxic epidermal necrolysis (grade 4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/25784657
1250 mg 1 times / day steady, oral Dose: 1250 mg, 1 times / day Route: oral Route: steady Dose: 1250 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25784657/	unhealthy, 51 years (range: 46 – 72 years) n = 3 Health Status: unhealthy Condition: NSCLC Age Group: 51 years (range: 46 – 72 years) Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/25784657/	Sources: https://pubmed.ncbi.nlm.nih.gov/25784657/
250 mg 1 times / day steady, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: steady Dose: 250 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf	unhealthy n = 102 Health Status: unhealthy Population Size: 102 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf	Disc. AE: Asthenia... AEs leading to discontinuation/dose reduction: Asthenia (grade 4, 1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf
500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf	unhealthy n = 114 Health Status: unhealthy Population Size: 114 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf	Disc. AE: Acne, Rash... AEs leading to discontinuation/dose reduction: Acne (grade 3, 2 patients) Rash (grade 2-3, 2 patients) Diarrhea (1 patient) Abdominal pain (1 patient) Headache (1 patient) Epistaxis (1 patient) Pruritus (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf

AEs

AE	Significance	Dose	Population
Toxic epidermal necrolysis	grade 4, 1 patient DLT	1000 mg 1 times / day steady, oral Dose: 1000 mg, 1 times / day Route: oral Route: steady Dose: 1000 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25784657	unhealthy, 51 years (range: 46 – 72 years) n = 4 Health Status: unhealthy Condition: NSCLC Age Group: 51 years (range: 46 – 72 years) Sex: M+F Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/25784657
Asthenia	grade 4, 1 patient Disc. AE	250 mg 1 times / day steady, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: steady Dose: 250 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf	unhealthy n = 102 Health Status: unhealthy Population Size: 102 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf
Abdominal pain	1 patient Disc. AE	500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf	unhealthy n = 114 Health Status: unhealthy Population Size: 114 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf
Diarrhea	1 patient Disc. AE	500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf	unhealthy n = 114 Health Status: unhealthy Population Size: 114 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf
Epistaxis	1 patient Disc. AE	500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf	unhealthy n = 114 Health Status: unhealthy Population Size: 114 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf
Headache	1 patient Disc. AE	500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf	unhealthy n = 114 Health Status: unhealthy Population Size: 114 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf
Pruritus	1 patient Disc. AE	500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf	unhealthy n = 114 Health Status: unhealthy Population Size: 114 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf
Rash	grade 2-3, 2 patients Disc. AE	500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf	unhealthy n = 114 Health Status: unhealthy Population Size: 114 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf
Acne	grade 3, 2 patients Disc. AE	500 mg 1 times / day steady, oral Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf	unhealthy n = 114 Health Status: unhealthy Population Size: 114 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 1478 P-gp 1461 CYP1A2 1524	CYP3A5 395 P-gp 1537	hepatic enzymes 1

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	no
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995Orig1s000ClinPharmR.pdf	no
hepatic enzymes 1	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995Orig1s000ClinPharmR.pdf	yes [Inhibition 11.2 uM]	yes (co-administration study) Comment: gefitinib increased auc of metoprolol by 35% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995Orig1s000ClinPharmR.pdf
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995Orig1s000ClinPharmR.pdf	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995Orig1s000ClinPharmR.pdf	major	yes (co-administration study) Comment: itraconazole increased auc of gefitinib by 80% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995Orig1s000ClinPharmR.pdf
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995Orig1s000ClinPharmR.pdf Page: 21.0	major	yes (pharmacogenomic study) Comment: CYP2D6 PMs have approximately 2-fold higher exposure to gefitinib than CYP2D6 EM Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995Orig1s000ClinPharmR.pdf Page: 21.0
CYP3A5 395	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995Orig1s000ClinPharmR.pdf Page: 21.0	minor	no (pharmacogenomic study) Comment: CYP3A5 genotype did not appear to impact gefitinib PK Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995Orig1s000ClinPharmR.pdf Page: 21.0
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995Orig1s000ClinPharmR.pdf	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Clinr.pdf

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:49668	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:49668
ChemicalBook	CB8120056	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8120056
MolPort	MolPort-000-883-335	https://www.molport.com/shop/molecule-link/MolPort-000-883-335
Selleck Chemicals	Gefitinib	http://www.selleckchem.com/products/Gefitinib.html
ZINC	ZINC000019632614	http://zinc15.docking.org/substances/ZINC000019632614
eMolecules	876432	https://www.emolecules.com/cgi-bin/more?vid=876432

PubMed

Title	Date	PubMed
New drugs in gynecologic cancer.	2001 Apr	12057130
Scoring a bull's-eye against cancer genome targets.	2001 Aug	11710731
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.	2001 Dec	11751524
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.	2001 Dec 15	11745477
OSI Pharmaceuticals, Genentech and Roche announce data from clinical studies of Tarceva.	2001 Jun	12113131
ZD-1839 (AstraZeneca).	2001 Mar	11575718
Targeted Therapies in the Treatment of Breast Cancer. Proceedings of a meeting. Kailua-Kona, Hawaii, July 19-23, 2000.	2001 Oct	11760720
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.	2001 Oct	11706398
Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.	2001 Oct	11706397
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.	2001 Oct 1	11585753
HER-targeted tyrosine-kinase inhibitors.	2002	12422050
Gefitinib.	2002	12381224
ZD1839 (Iressa): what's in it for the patient?	2002	12202785
Finding the needle in the haystack: why high-throughput screening is good for your health.	2002	12100740
ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.	2002 Apr 8	11953865
[Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].	2002 Feb	11904986
Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing.	2002 Jan	11863116
ZD1839 (Iressa): preclinical studies and pharmacology.	2002 Jan-Feb	11989913
Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC.	2002 Jul-Aug	12415815
Tyrosine kinase signal transduction inhibitors. Clinical trials.	2002 Jul-Aug	12415814
The rational basis of using novel targeted biological agents in non-small cell lung cancer.	2002 Jul-Aug	12415813
Gateways to Clinical Trials. June 2002.	2002 Jun	12168506
Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies.	2002 Jun	12119458
[Progress in diagnosis and treatment of lung cancer].	2002 Mar 20	11989256
ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.	2002 Mar 20	11920601
Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.	2002 Mar 4	11875748
Despite concerns, FDA panel backs EGFR inhibitor.	2002 Nov 6	12419780
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).	2002 Oct	12374696
Surprise phase III failure for ZD1839.	2002 Oct	12372708
Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.	2002 Sep	12207609

Patents

Sample Use Guides

In Vivo Use Guide

250 mg orally once a day

Route of Administration: Oral

In Vitro Use Guide

Gefitinib could inhibit highly expressed EGFR cell growth in a dose-dependent manner in the range of dose from 0.10 to 102.4 uM

Name

Type

Language

GEFITINIB

Official Name

English

gefitinib [INN]

Common Name

English

GEFITINIB [USAN]

Common Name

English

NSC-759856

Code

English

4-QUINAZOLINAMINE, N-(3-CHLORO-4-FLUOROPHENYL)-7-METHOXY-6-(3-4-MORPHOLIN)PROPOXY)-

Common Name

English

GEFITINIB [EMA EPAR]

Common Name

English

ZD-1839

Code

English

GEFITINIB [VANDF]

Common Name

English

IRESSA

Brand Name

English

Gefitinib [WHO-DD]

Common Name

English

GEFITINIB [JAN]

Common Name

English

GEFITINIB [EP MONOGRAPH]

Common Name

English

GEFITINIB [ORANGE BOOK]

Common Name

English

GEFITINIB [MART.]

Common Name

English

GEFITINIB [MI]

Common Name

English

ZD1839

Code

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/18/2075